| Description | Lansoprazole (A-65006) is a 2, 2, 2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) |
| In vitro | Lansoprazole对缺血-再灌注或吲哚美辛诱发的肠损伤有明显的抑制作用.外源施用Lansoprazol可以防止小肠中缺血-再灌注或吲哚美辛诱导的损伤.Lansoprazole抑制缺血-再灌注或吲哚美辛诱导的大鼠急性炎性反应以及肠粘膜损伤. |
| In vivo | Lansoprazole是一种很强的抗分泌剂,通过抑制胃氢/钾的腺苷三磷酸酶抑制胃酸分泌（H +,K + - ATP酶）。Lansoprazole抑制血管粘附分子的表达增加,中性粒细胞的激活,以及从激活的内皮细胞产生促炎细胞因子。Lansoprazole在胃上皮细胞中诱导包括II期解毒酶（NADPH-泛醌氧化还原酶,谷胱甘肽S-转移酶）和抗氧化应激蛋白（HO-1,硫氧还蛋白还原酶和超氧化物歧化酶）在内的多种基因的表达。Lansoprazole在大鼠胃上皮细胞中,上调HO-1表达,并且有抗炎作用。 |
| Synonyms | 兰索拉唑, A-65006, AG-1749 |
| molecular weight | 369.36 |
| Molecular formula | C16H14F3N3O2S |
| CAS | 103577-45-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | 1eq. HCl: 18.5 mg/mL (50 mM) DMSO: 50 mg/mL (135.37 mM) |
| References | 1. Garnett WR, et al. Ann Pharmacother, 1996, 30(12), 1425-1436. 2. Takagi T, et al. J Clin Biochem Nutr, 2009, 45(1), 9-13. 3. Kang D, Pang X, Lian W, et al. Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches[J]. RSC Advances. 2018 Jan 8(10): 5286-5297. |
| Citations | 1. Kang D, Pang X, Lian W, et al. Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches. RSC Advances. 2018 Jan 8(10): 5286-5297. |